A Phase 2 interventional study of AXS-05 and Bupropion in Major Depressive Disorder, sponsored by Axsome Therapeutics, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-09-24.
Sponsored by Axsome Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Depressive Disorder, Major by Axsome Therapeutics, Inc. — 2 open to participants now, 2 under way, 1 of them phase 3. Depressive Disorder, Major · Axsome Therapeutics, Inc..
Among the 10 studies in Depressive Disorder, Major by Axsome Therapeutics, Inc., this one is the 9th largest by enrollment, is the only one that started in 2018, is one of 4 in phase 2, and was the 2nd registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →2 of the 10 studies in Depressive Disorder, Major by Axsome Therapeutics, Inc. are open now, in 1 country. Recruiting first, the newest first:
Axsome Therapeutics, Inc. · Sites in United States
Ages 18–65
Axsome Therapeutics, Inc. · Sites in United States
Ages 18–65
By country, each count listing its studies:
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 1 started in 2018.
This study's enrollment of 97 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 320 across the 10 interventional studies. Of the 7 that completed or were terminated, 4 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
Axsome Therapeutics, Inc. is the lead sponsor of 37 studies on the registry; 12 are open to participants now.
Of its 21 completed or terminated interventional studies of FDA-regulated products, 12 (57%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Depressive Disorder, Major by Axsome Therapeutics, Inc., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Randomized, Double-Blind, Active-Controlled Study of AXS-05 for MDD.
This study will evaluate the safety and efficacy of AXS-05 in a randomized, double-blind, active-controlled study in patients diagnosed with major depressive disorder (MDD) experiencing an acute episode.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: AXS-05
Drug: Bupropion
MADRS Score - Overall Change From Baseline
The primary objective of the study was to assess the effect of AXS-05 versus bupropion as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) for change in severity of depressive symptoms. The MADRS is a 10-item scale and items are scored between 0-6 points. For each item, a score of 0 indicates the absence of symptoms, and a score of 6 indicates symptoms of maximum severity. A maximum total score is 60 points.
Time frame: Assessed at week 1, 2, 3, 4, 5 and 6 (averaged over the entire 6-week treatment period)
MADRS Score - Change From Baseline to Week 6
The primary objective of the study was to assess the effect of AXS-05 versus bupropion as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) for change in severity of depressive symptoms. The MADRS is a 10-item scale and items are scored between 0-6 points. For each item, a score of 0 indicates the absence of symptoms, and a score of 6 indicates symptoms of maximum severity. A maximum total score is 60 points.
Time frame: 6 weeks
| Milestone | AXS-05 | Bupropion |
|---|---|---|
| Started | 48 | 49 |
| Mitt population | 43 | 37 |
| Safety population | 48 | 48 |
| Completed | 38 | 35 |
| Not completed | 10 | 14 |
The primary objective of the study was to assess the effect of AXS-05 versus bupropion as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) for change in severity of depressive symptoms. The MADRS is a 10-item scale and items are scored between 0-6 points. For each item, a score of 0 indicates the absence of symptoms, and a score of 6 indicates symptoms of maximum severity. A maximum total score is 60 points.
| score on a scale | AXS-05 | Bupropion |
|---|---|---|
| MADRS Score - Overall Change From Baseline | 13.7 ± 0.63 | 8.8 ± 0.68 |
The primary objective of the study was to assess the effect of AXS-05 versus bupropion as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) for change in severity of depressive symptoms. The MADRS is a 10-item scale and items are scored between 0-6 points. For each item, a score of 0 indicates the absence of symptoms, and a score of 6 indicates symptoms of maximum severity. A maximum total score is 60 points.
| score on a scale | AXS-05 | Bupropion |
|---|---|---|
| MADRS Score - Change From Baseline to Week 6 | 17.2 ± 1.4 | 12.1 ± 1.5 |
Collected over Adverse events were collected from the time of signing the ICF through 30 days after the last study visit or Early Termination (ET), whichever occurred first, an average of 11 weeks per participant.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AXS-05 | 0/48 (0%) | 0/48 (0%) | 35/48 (72.9%) |
| Bupropion | 0/48 (0%) | 0/48 (0%) | 30/48 (62.5%) |
| Event | AXS-05 | Bupropion |
|---|---|---|
| DizzinessNervous system disorders | 10/48 | 2/48 |
| NauseaGastrointestinal disorders | 8/48 | 6/48 |
| Dry mouthGastrointestinal disorders | 5/48 | 4/48 |
| Decreased appetiteMetabolism and nutrition disorders | 5/48 | 4/48 |
| HeadacheNervous system disorders | 4/48 | 5/48 |
| AnxietyPsychiatric disorders | 5/48 | 1/48 |
| ConstipationGastrointestinal disorders | 3/48 | 4/48 |
| DiarrheaGastrointestinal disorders | 3/48 | 4/48 |
| InsomniaPsychiatric disorders | 4/48 | 2/48 |
| SedationNervous system disorders | 3/48 | 0/48 |
Participants randomized
| Age, Continuous(years) | AXS-05 | Bupropion | Total |
|---|---|---|---|
| Mean | 38.8 ± 11.98 | 39.9 ± 12.96 | 39.1 ± 12.34 |
| Sex: Female, Male(Participants) | AXS-05 | Bupropion | Total |
|---|---|---|---|
| Female | 28 | 32 | 60 |
| Male | 20 | 17 | 37 |
| Race (NIH/OMB)(Participants) | AXS-05 | Bupropion | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 15 | 16 | 31 |
| White | 32 | 29 | 61 |
| More than one race | 0 | 4 | 4 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — via publication
Ran from May 2018 to primary completion in Jan 2019, 7 months.
Results were first posted in Sep 2021, 2 years 8 months after primary completion.
Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's 7 months is below that.
Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dextromethorphan/Bupropion Tablet AXS-05